Triptorelin embonate: a 6-month formulation for prostate cancer

By Whelan Peter  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 17, 2010-12 ,pp. : 2929-2932

Informa Healthcare

Access to resources Recommend Favorite

An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

By Stadler Walter M.   Vaughn David J.   Sonpavde Guru   Vogelzang Nicholas J.   Tagawa Scott T.   Petrylak Daniel P.   Rosen Peter   Lin Chia-Chi   Mahoney John   Modi Sanjiv   Lee Peter   Ernstoff Marc S.   Su Wu-Chou   Spira Alexander   Pilz Korinna   Vinisko Richard   Schloss Charles   Fritsch Holger   Zhao Charles   Carducci Michael A.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 976-982

Blackwell Publishing

Access to resources Recommend Favorite

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non–small cell lung cancer

By Doebele Robert C.   Spigel David   Tehfe Mustapha   Thomas Sachdev   Reck Martin   Verma Sunil   Eakle Janice   Bustin Frederique   Goldschmidt Jerome   Cao Dachuang   Alexandris Ekaterine   Yurasov Sergey   Camidge D. Ross   Bonomi Philip  

Cancer, Vol. 121, Iss. 6, 2015-03 ,pp. : 883-892

Blackwell Publishing

Access to resources Recommend Favorite

Triptorelin embonate (6-month formulation): a guide to its use in advanced prostate cancer

By  

Drugs & Therapy Perspectives, Vol. 26, Iss. 6, 2010-06 ,pp. : 5-7

Adis International

Access to resources Recommend Favorite

An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma

By Reichardt Peter   Oechsle Karin   Pink Daniel   Bokemeyer Carsten   Schneller F.   Issels Rolf   Kanz Lothar   Hartmann Jörg Thomas  

Investigational New Drugs, Vol. 21, Iss. 4, 2003-11 ,pp. : 481-486

Springer Publishing Company

Access to resources Recommend Favorite